Studies using Ba/F3 cells, patient-derived cells, organoids, and xenografts with various Exon20ins demonstrated that amivantamab inhibits tumor growth by reducing EGFR-MET levels and enhancing immune response, indicated by increased IFNγ secretion. This evidence concerns the gene EGFR and neoplasm.